BIOSTAGE, INC. (NASDAQ:BSTG) Files An 8-K Regulation FD DisclosureItem 7.01.
On July 10, 2017, Biostage, Inc. (the “Company”) issued a press release announcing that the Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for continued listing on Nasdaq and accepted the Company’s plan to regain compliance with the continued listing requirements, including Listing Rule 5550(a)(2), which requires an issuer to maintain a closing bid price of at least $1.00 per share, and Listing Rule 5550(b)(1), which requires a minimum stockholders equity of $2.5 million. The Company’s continued listing is subject to a number of conditions, with the Panel’s decision ultimately requiring that the Company evidence full compliance with all requirements for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million stockholders’ equity requirements, by no later than November 13, 2017. A copy of the Press Release is being filed as Exhibit 99.1 hereto, which is incorporated by reference herein.
The information disclosed under this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number | Title |
| 99.1 | Press Release issued by Biostage, Inc. on July 10, 2017. |
Biostage, Inc. ExhibitEX-99.1 2 v470547_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Biostage Granted Continued Listing on Nasdaq Holliston,…To view the full exhibit click here
About BIOSTAGE, INC. (NASDAQ:BSTG)
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.
